Effect of Biofield Energy Healing Based Herbomineral Formulation on Pro-inflammatory Cytokines Expression in Biofield Treated Mouse Splenocyte Cells: Impact of the Trivedi Effect®
K. Vagt. American Journal of BioScience4 (6):
74-83(December 2017)Biofield Energy Healing Treatment, Biofield Energy Healers, The Trivedi Effect®, Inflammation, Immunomodulation, Splenocytes, Cytokines, ELISA.
A proprietary herbomineral formulation was formulated with four ingredients; a mixture of the minerals (zinc, magnesium, and selenium) and the herbal root extract ashwagandha. The aim of the study was to evaluate the immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect®) on the herbomineral formulation in splenocyte cells, which were isolated from Biofield Treated mice. The test formulation was divided into two parts. One part was denoted as the control without any Biofield Energy Treatment, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Healing Treatment remotely from seven renowned Biofield Energy Healers. The splenocyte cells were treated with the test formulation at concentrations ranges from 0.00001053 to 10.53 µg/mL and analyzed after 48 hours of treatment by MTT assay. The cell viability data showed safe concentrations up to 1.053 µg/mL with viability ranges from 69.22% to 123.88% in the test formulation groups. The expression of TNF-α was decreased by 4.82% at 1.053 µg/mL in the Biofield Energy Treated test formulation compared with the vehicle control. The level of TNF-α was significantly decreased by 2.02%, 4.92%, and 18.78% at 0.00001053, 0.001053, and 1.053 µg/mL, respectively in the Biofield Energy Treated test formulation group as compared to the untreated test formulation. The expression of IL-1β was significantly reduced by 83.65%, 92.15%, 27.30%, and 41.88% at 0.00001053, 0.0001053, 0.001053, and 1.053 µg/mL, respectively in the Biofield Energy Treated test formulation compared with the vehicle control. The Biofield Treated test formulation showed significant reduction of IL-1β by 17.26%, 92.61% (p≤0.001), 34.62% (p≤0.05), and 16.13% at 0.00001053, 0.0001053, 0.001053, and 1.053 µg/mL, respectively compared with the untreated test formulation. Additionally, the expression of chemokine MIP-1α was significantly reduced by 17.03%, 10.99%, 22.33%, 24.21%, 21.61%, and 30.67% at 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053, and 1.053 µg/mL, respectively in the Biofield Treated test formulation compared with the vehicle control. The MIP-1α expression was significantly reduced by 19.32% and 12.56% at 0.01053 and 0.1053 µg/mL, respectively in the Biofield Treated test formulation compared with the untreated test formulation. The overall results demonstrated that the Biofield Energy Treated test formulation significantly down-regulated the expression of TNF-α, IL-1β, and MIP-1α in the Biofield Treated mice splenocyte cells compared to the untreated test formulation. These data suggest that the Biofield Treated test formulation can be used for autoimmune and inflammatory diseases, stress management and anti-aging by improving overall health.